Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBT Margin: 2011-2025

Historic EBT Margin for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to 20.71%.

  • Aytu Biopharma's EBT Margin rose 511.00% to 14.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.85%, marking a year-over-year decrease of 1865.00%. This contributed to the annual value of 20.71% for FY2025, which is 478.00% down from last year.
  • Latest data reveals that Aytu Biopharma reported EBT Margin of 20.71% as of FY2025, which was down 30.05% from 15.92% recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's EBT Margin ranged from a high of 15.88% in FY2023 and a low of 112.64% during FY2022.
  • Its 3-year average for EBT Margin is 17.50%, with a median of 15.92% in 2024.
  • As far as peak fluctuations go, Aytu Biopharma's EBT Margin tumbled by 3,912bps in 2021, and later surged by 9,676bps in 2023.
  • MRY analysis of 5 years shows Aytu Biopharma's EBT Margin stood at 88.42% in 2021, then dropped by 27bps to 112.64% in 2022, then soared by 86bps to 15.88% in 2023, then dropped by 0bps to 15.92% in 2024, then crashed by 30bps to 20.71% in 2025.
  • Its EBT Margin stands at 20.71% for FY2025, versus 15.92% for FY2024 and 15.88% for FY2023.